BIOMAT Database Logo BIOMAT Database Logo

Semen and serum pharmacokinetics of zidovudine and zidovudine-glucuronide in men with HIV-1 infection. 2000

P L Anderson, and S E Noormohamed, and K Henry, and R C Brundage, and H H Balfour, and C V Fletcher
Department of Experimental and Clinical Pharmacology, University of Minnesota Academic Health Sciences Center, Minneapolis, USA.

OBJECTIVE To characterize the concentration-time profiles of zidovudine and zidovudine-glucuronide in semen and serum of men infected with the human immunodeficiency-1 virus (HIV-1). METHODS Open-label observational study. METHODS University-affiliated teaching hospital and research center. METHODS Four asymptomatic HIV-1-infected men. METHODS Zidovudine administration was followed by an 8-hour intensive pharmacokinetic study on day 1. Over the next 8 days, a dose administration and timed single-sample strategy was employed to determine serum and semen concentration time profiles simultaneously. RESULTS Zidovudine and zidovudine-glucuronide concentrations were uniformly higher in semen than in serum except at 1 hour after the dose. The median area under the curve ratio (semen AUC0-48:serum AUC0-infinity) was 3.31 for zidovudine and 15.04 for zidovudine-glucuronide. CONCLUSIONS Zidovudine and zidovudine-glucuronide reach high levels in seminal plasma relative to serum. The virologic, pharmacodynamic, and public health implications of distribution to this compartment require further study.

UI MeSH Term Description Entries
D008297 Male Males
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012661 Semen The thick, yellowish-white, viscid fluid secretion of male reproductive organs discharged upon ejaculation. In addition to reproductive organ secretions, it contains SPERMATOZOA and their nutrient plasma. Seminal Plasma,Plasma, Seminal
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV
D019540 Area Under Curve A statistical means of summarizing information from a series of measurements on one individual. It is frequently used in clinical pharmacology where the AUC from serum levels can be interpreted as the total uptake of whatever has been administered. As a plot of the concentration of a drug against time, after a single dose of medicine, producing a standard shape curve, it is a means of comparing the bioavailability of the same drug made by different companies. (From Winslade, Dictionary of Clinical Research, 1992) AUC,Area Under Curves,Curve, Area Under,Curves, Area Under,Under Curve, Area,Under Curves, Area

Related Publications

P L Anderson, and S E Noormohamed, and K Henry, and R C Brundage, and H H Balfour, and C V Fletcher
Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men.
June 2008, Journal of acquired immune deficiency syndromes (1999),
P L Anderson, and S E Noormohamed, and K Henry, and R C Brundage, and H H Balfour, and C V Fletcher
Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection.
October 1993, Annals of internal medicine,
P L Anderson, and S E Noormohamed, and K Henry, and R C Brundage, and H H Balfour, and C V Fletcher
Pharmacokinetics of raltegravir in the semen of HIV-infected men.
January 2014, Antiviral therapy,
P L Anderson, and S E Noormohamed, and K Henry, and R C Brundage, and H H Balfour, and C V Fletcher
Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in children with HIV infection.
May 1995, British journal of clinical pharmacology,
P L Anderson, and S E Noormohamed, and K Henry, and R C Brundage, and H H Balfour, and C V Fletcher
Semen alterations in HIV-1 infected men.
August 2002, Human reproduction (Oxford, England),
P L Anderson, and S E Noormohamed, and K Henry, and R C Brundage, and H H Balfour, and C V Fletcher
Bleeding tendency, platelet function, and pharmacokinetics of ibuprofen and zidovudine in HIV(+) hemophilic men.
July 1992, American journal of hematology,
P L Anderson, and S E Noormohamed, and K Henry, and R C Brundage, and H H Balfour, and C V Fletcher
No effect of zidovudine on hepatitis B virus replication in homosexual men with symptomatic HIV-1 infection.
February 1991, AIDS (London, England),
P L Anderson, and S E Noormohamed, and K Henry, and R C Brundage, and H H Balfour, and C V Fletcher
[Placental villous lesions in HIV-1 infection treated with zidovudine].
May 2011, Ginecologia y obstetricia de Mexico,
P L Anderson, and S E Noormohamed, and K Henry, and R C Brundage, and H H Balfour, and C V Fletcher
Myopathy with human immunodeficiency virus type 1 (HIV-1) infection: HIV-1 or zidovudine?
October 1990, Annals of internal medicine,
P L Anderson, and S E Noormohamed, and K Henry, and R C Brundage, and H H Balfour, and C V Fletcher
Zidovudine plus didanosine in primary HIV-1 infection.
January 1997, Antiviral therapy,
Copied contents to your clipboard!